Will Next-Generation Agents Deliver on the Promise of Epigenetic Hypomethylation Therapy?

References

• Issa JP . Aging and epigenetic drift: a vicious cycle . J. Clin. Invest.124 ( 1 ), 24 – 29 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lynch M . Rate, molecular spectrum, and consequences of human mutation . Proc. Natl Acad. Sci. USA107 ( 3 ), 961 – 968 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Momparler R , GoodmanJ . In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine . Cancer Res.37 ( 6 ), 1636 – 1639 ( 1977 ).
   PubMed Web of Science ®Google Scholar
• Oki Y , IssaJP . Epigenetic mechanisms in AML – a target for therapy . Cancer Treat. Res.145 , 19 – 40 ( 2010 ).
   PubMedGoogle Scholar
• Karahoca M , MomparlerRL . Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy . Clin. Epigenetics5 ( 3 ), 1 – 16 ( 2013 ).
   PubMedGoogle Scholar
• Negrotto S , NgKP , JankowskaAMet al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors . Leukemia26 ( 2 ), 244 – 254 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Issa JP , Garcia-ManeroG , GilesFJet al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies . Blood103 ( 5 ), 1635 – 1640 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y . Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes . Hematology Am. Soc. Hematol. Educ. Program2013 , 511 – 521 ( 2013 ).
   PubMedGoogle Scholar
• Oki Y , JelinekJ , ShenL , KantarjianHM , IssaJP . Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia . Blood111 ( 4 ), 2382 – 2384 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kantarjian H , OkiY , Garcia-ManeroGet al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia . Blood109 ( 1 ), 52 – 57 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Derissen EJ , BeijnenJH , SchellensJH . Concise drug review: azacitidine and decitabine . Oncologist18 ( 5 ), 619 – 624 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yang AS , DoshiKD , ChoiSWet al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia . Cancer Res.66 ( 10 ), 5495 – 5503 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Chuang JC , YooCB , KwanJMet al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine . Mol. Cancer Ther.4 ( 10 ), 1515 – 1520 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Qin T , YoussefEM , JelinekJet al. Effect of cytarabine and decitabine in combination in human leukemic cell lines . Clin. Cancer. Res.13 ( 14 ), 4225 – 4232 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Kantarjian H , IssaJP , RosenfeldCSet al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study . Cancer106 ( 8 ), 1794 – 1803 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Steensma DP , BaerMR , SlackJLet al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for Outpatient Treatment (ADOPT) trial . J. Clin. Oncol.27 ( 23 ), 3842 – 3848 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Bordoni RE , FeinbergBA , GilmoreJWet al. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice . Clin. Lymphoma Myeloma Leuk.4 , 350 – 354 ( 2011 ).
   Google Scholar
• Fenaux P , MuftiGJ , Hellstrom-LindbergEet al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia . J. Clin. Oncol.28 ( 4 ), 562 – 569 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Qin T , CastoroR , El AhdabSet al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome . PLoS ONE6 ( 8 ), e23372 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM , SaidR , CulottaKet al. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy . Clin. Epigenetics7 ( 1 ), 29 ( 2015 ).
   PubMedGoogle Scholar
• Stewart DJ , IssaJP , KurzrockRet al. Decitabine effect on tumor global DNA methylation and other parameters in a Phase I trial in refractory solid tumors and lymphomas . Clin. Cancer Res.15 ( 11 ), 3881 – 3888 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chuang JC , WarnerSL , VollmerDet al. S110, a 5-aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth . Mol. Cancer Ther.9 ( 5 ), 1443 – 1450 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tellez CS , GrimesMJ , PicchiMAet al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome . Int. J. Cancer135 ( 9 ), 2223 – 2231 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wang Y , CardenasH , FangFet al. Epigenetic targeting of ovarian cancer stem cells . Cancer Res.74 ( 17 ), 4922 – 4936 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Issa J-P , RobozG , RizzieriDet al. Pharmacokinetic and pharmacodynamic-guided Phase 1 study of the novel hypomethylating drug guadecitabine (SGI-110) in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) . Lancet Oncol.16 ( 9 ), 1099 – 1110 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Garcia Manero G , Ritchie , WalshKet al. First clinical results of a randomized Phase 2 dose-response study of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in 102 patients with intermediate (Int) or high risk (HR) myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) . Blood124 ( 21 ), Abstract 529 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kantarjian H , JabbourE , YeeKet al. First clinical results of a randomized Phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) . Blood122 ( 21 ), Abstract 497 ( 2013 ).
   Web of Science ®Google Scholar
• Ferraris D , DuvallB , DelahantyGet al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase . J. Med. Chem.57 ( 6 ), 2582 – 2588 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Laille E , SavonaMR , ScottBL , BoydTE , DongQ , SkikneB . Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies . J. Clin. Pharmacol.54 ( 6 ), 630 – 639 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mistry B , JonesM , KubiakPet al. A Phase 1 study to assess the absolute bioavailability and safety of an oral solution of decitabine in subjects with myelodysplastic syndromes (MDS) . Blood118 ( 21 ), Abstract 3801 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G , GoreSD , CogleCet al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia . J. Clin. Oncol.29 ( 18 ), 2521 – 2527 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials Database: NCT01757535 . http://clinicaltrials.gov/ct2/show/NCT.01757535 .
   Google Scholar
• ClinicalTrials Database: NCT01566695 . http://clinicaltrials.gov/ct2/show/NCT01566695 .
   Google Scholar
• Lavelle D , VaitkusK , LingYet al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine . Blood119 ( 5 ), 1240 – 1247 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Oganesian A , RedkarS , TavernaP , Joshi-HangalR , AzabM . Preclinical data in cynomolgus (cyn) monkeys of ASTX-727, a novel oral hypomethylating agent (HMA) composed of low-dose oral decitabine combined with a novel cytidine deaminase inhibitor (CDAi) E7727 . Blood122 ( 21 ), Abstract 2526 ( 2013 ).
   Web of Science ®Google Scholar
• ClinicalTrials Database: NCT02103478 . http://clinicaltrials.gov/ct2/show/NCT02103478 .
   Google Scholar
• ClinicalTrials Database: NCT02348489 . http://clinicaltrials.gov/ct2/show/NCT02348489 .
   Google Scholar
• Fleming G , GhamandeS , LinYet al. Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA) . Cancer Res.74 ( 20 ), Abstract 2320 ( 2014 ).
   PubMedGoogle Scholar
• El-Khoueiry A , MulcahyMF , Bekaii-SaabTet al. Pharmacodynamic (PD) and pharmacokinetic (PK) results of the second-generation hypomethylating agent, SGI-110, in patients with hepatocellular carcinoma (HCC) after progression on sorafenib . Presented at : American Association for Cancer Research (AACR) 106th Annual Meeting . Philadelphia, PA, USA , 18–22 April 2015 .
   Google Scholar
• Fang F , MunckJ , TangJet al. The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer . Clin. Cancer Res.20 ( 24 ), 6504 – 6516 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Covre A , CoralS , Di GiacomoAM , TavernaP , AzabM , MaioM . Epigenetics meets immune checkpoints . Semin. Oncol.42 ( 3 ), 506 – 513 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Coral S , ParisiC , NicolayHJet al. Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide . Cancer Immunol. Immunother.62 ( 3 ), 605 – 614 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Srivastava P , PaluchBE , MatsuzakiJet al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts . Leuk. Res.38 ( 11 ), 1332 – 1341 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Srivastava P , PaluchBE , MatsuzakiJet al. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts . Epigenetics10 ( 3 ), 237 – 246 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Pulliam N , TavernaP , LyonsJet al. Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer . Presented at : American Association for Cancer Research (AACR) 106th Annual Meeting . Philadelphia, PA, USA , 18–22 April 2015 .
   Google Scholar
• Muvarak NE , RobertC , NagariaPKet al. Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for poor prognosis acute myeloid leukemia . Presented at : American Association for Cancer Research (AACR) 106th Annual Meeting . Philadelphia, PA, USA , 18–22 April 2015 .
   Google Scholar